Kazakhstan’s growing role as a treatment destination sits alongside an established market for care abroad. That tells us more about different patient needs than a simple vote of confidence in one country’s hospitals.
While Kazakhstan promotes its hospitals to foreign patients, some of its own citizens are traveling in the opposite direction. South Korea’s official medical tourism portal lists 14,475 patients from Kazakhstan in 2024. Uzbekistan recorded 8,224 arrivals by Kazakh citizens for treatment in 2025.
Those journeys complicate the familiar story of Kazakhstan becoming a regional medical hub. They do not disprove it.
A country can offer treatment that attracts people from abroad while its residents seek something different elsewhere. Price, access to a particular doctor, family connections and the wish for another opinion can all shape an individual decision.
The harder task is separating those reasons. The available numbers show that care crosses Kazakhstan’s borders in both directions. They do not tell us how many departures reflect a missing treatment, a difficult local referral or a preference for an overseas provider.
Two outbound routes, two different measures
The Korea figure comes from Medical Korea’s 2024 nationality statistics, published by the Korea Health Industry Development Institute, known as KHIDI. Its explanation says the count is based on patients at hospitals, excluding repeated treatments and visits within that measure.
It should not be read as a count of border crossings or assumed to be a fully deduplicated total of people across every hospital.
The Uzbekistan number comes from its National Statistics Committee’s release for January–December 2025. That records foreign citizens arriving for treatment, including 8,224 from Kazakhstan.
The years and methods differ. Adding the two figures would not produce a valid annual total for Kazakhstan’s outbound medical tourism. Nor do they establish where all Kazakh patients go: these are documented routes, not a complete map.
They do establish something useful. Outbound care includes travel to a nearby Central Asian country as well as to South Korea. An account focused only on wealthy families choosing distant premium hospitals would miss part of the market.
Neither release provides enough detail to assign motives to those patients. We cannot infer income, diagnosis or satisfaction with Kazakhstan’s healthcare system from nationality alone.
Travel abroad does not mean the same thing for every patient
A person seeking a highly specialized opinion and someone arranging a planned procedure near relatives may both appear in a medical travel count. Their reasons for leaving home could be very different.
That makes the usual question—why don’t they trust local hospitals?—too narrow. It assumes the answer before the evidence has been collected.
Trust can matter, but it is only one possible explanation. A patient might trust a local doctor and still be referred abroad for a service. Another might have an appropriate treatment available at home but prefer the way an overseas team explains the options.
These are illustrative situations, not findings from a survey of Kazakh travelers. A representative patient study would be needed to establish how common each reason is.
The distinction also changes how policymakers should respond. If departures are driven by a specific missing service, investment or a formal referral agreement may help. If the problem is uncertainty about where to obtain existing care, better referral information may be more useful than another building.
If patients mainly want a second opinion, the relevant service might be a reliable review of records rather than an overseas admission. Treating every departure as the same kind of failure would lead to poorly targeted solutions.
Korea actively builds relationships in Kazakhstan
The route to South Korea is supported by organized promotion, not simply by individual patients discovering a hospital online.
KHIDI’s notice for Medical Korea in Kazakhstan in 2024 sought about 20 participating medical institutions and patient-attraction businesses. The program covered Almaty and Astana, with hospital promotion and one-to-one business meetings. Its stated purpose included expanding patient recruitment and local networks.
That provides a concrete explanation for how a treatment route can become easier to use. Organizations meet, referral contacts develop and information about overseas services becomes more available.
It does not show that every referral produced by such activity was clinically necessary, or that the event caused a particular increase in patient numbers. Marketing activity and treatment outcomes are different forms of evidence.
For Kazakhstan’s hospitals, this is a competitive issue even when their clinical services are strong. Patients have to find them, understand what they offer and receive a useful response. An unanswered inquiry creates room for another provider to become the more familiar choice.
The lesson is not that domestic hospitals need more ambitious claims. They need a dependable way to explain which cases they can treat and when an outside opinion is appropriate.
Care in the capital does not settle access across the country
Kazakhstan’s domestic healthcare picture is more varied than a list of flagship hospitals suggests. The European Observatory’s 2024 health system review, published with WHO Europe, reported that 82.8% of doctors were based in urban areas.
“Staffing in rural areas is still challenging,” the review’s summary states.
The same review describes efforts to strengthen primary care and improve access in remote communities. It also records progress in financial protection: patients’ direct payments fell from 34% of total health spending in 2019 to 25% in 2021.
Those are historical system indicators, not measurements of medical tourism. They help explain why the experience of accessing care can differ within one country, but they do not prove that rural staffing shortages caused any particular patient to travel abroad.
For a resident far from a specialist center, “available in Kazakhstan” and “easy to obtain” are not identical. A domestic referral can still involve travel, accommodation, time off work and coordination between institutions.
That suggests a useful question for future research: did the patient compare an overseas provider with a local clinic, or with a specialist hospital in another Kazakh city? Those are different decisions, with different costs.
It also cautions against labeling particular cities as medically inadequate without specialty-level evidence. A national pattern of urban concentration cannot establish that a given hospital lacks the treatment a patient needs.
Investment can change the choices people face
At Astana’s oncology center, the government described a proton therapy service designed for up to 1,000 patients annually during its November 2025 inspection. That provides an example of domestic capability expanding in a field associated with international medical travel.
It does not show how many outbound journeys the service has replaced. That would require tracking eligible patients, treatment availability and what those patients would otherwise have done.
A new service can attract visitors and help residents at the same time. Whether it does so depends on the way appointments, staffing and funding are organized.
For example, an international patient department may make it easier for a foreign family to submit records. The useful domestic question is whether a resident referred from another region can obtain similarly clear instructions and a timely decision.
Hospitals could learn from comparing those two processes. If one is straightforward and the other is confusing, the problem may lie in administration rather than in the availability of a treatment.
That is a more actionable question than asking whether people should feel greater national pride in local medicine. Confidence grows through a sequence of experiences: the right referral, an explanation that makes sense, a bill that matches expectations and follow-up that happens when promised.
Sometimes the medical expertise travels instead
Competition between destinations is not the only possible model. A Korean provider’s agreement in Almaty offers a small example of international care being brought closer to patients.
According to OPEN Healthcare’s own announcement, its Kazakhstan operation and Suji Maria Hospital signed a cooperation agreement in September 2024. The company reported that 14 couples attended a joint infertility treatment session over three days.
This is a provider’s account of a partnership and an initial event. It is not independent evidence of pregnancy rates, long-term outcomes or a reduction in travel abroad.
Its significance is organizational. It shows that an overseas connection can involve clinicians working with a local service, rather than every patient boarding a flight.
Other arrangements could include case reviews or shared follow-up, where permitted and clinically appropriate. Those possibilities need clear rules about who makes decisions and who is responsible for the patient.
A foreign brand on the clinic door is not enough. Patients need to know which doctor will see them, what the overseas partner actually contributes and whether any part of the recommended care still requires travel.
The return journey deserves its own plan
A completed treatment abroad does not necessarily end the need for care. Returning patients may need their records reviewed, medicines reconciled or a further appointment organized.
The American College of Surgeons’ statement on medical and surgical tourism recommends obtaining complete records and arranging follow-up at home before travel whenever possible. Although written for US patients, that continuity-of-care principle is relevant to people returning to Kazakhstan as well.
For an illustrative patient coming home from Seoul, the practical issue could be as simple as whether the discharge report is available in a language the receiving clinician can use. More complex questions concern who will review a new symptom and how the original treating team will participate.
Those arrangements should be agreed between providers, with the patient’s consent. It is unreasonable to assume a local clinician will automatically take over a treatment plan they have not seen or discussed.
This is also a service opportunity for Kazakhstan’s health system. Good local follow-up can benefit residents who choose overseas care without requiring domestic hospitals to endorse every foreign provider or treatment.
A better measure than persuading everyone to stay
A fall in outbound patient numbers would not automatically mean Kazakhstan’s healthcare had improved. It could reflect better local options, but it could also reflect reduced ability to pay or difficulties traveling. A rise could indicate unmet need, greater choice or stronger overseas promotion.
The count needs context.
Useful research would ask patients what service they sought, whether they obtained a local referral, what alternatives they considered and how the care was funded. It would also distinguish an initial consultation from a full course of treatment.
The government’s 2026–2030 healthcare quality plan calls for a stronger role for patients in evaluating services. Medical travelers could contribute to that work by explaining specific failures or strengths in the care they encountered before departure and after returning.
For hospitals, the most useful finding might be quite ordinary: patients did not know a service existed, could not secure a referral or could not get their questions answered. Those problems call for different remedies from a genuine gap in clinical capability.
A successful system should make it easier to receive appropriate care at home and to obtain a well-managed referral elsewhere when needed. For the person holding medical records from two countries, the immediate test is whether the next doctor can continue the care without making them start again.